Researchers have revealed that arteriviruses may produce more mRNAs and proteins than previously understood – a finding that could provide insight on how the virus may potentially evolve to infect humans.
Browsing: Disease Area > Viral
Despite significant advances in the treatment of human immunodeficiency virus (HIV), there remain challenges. This review highlights recent advances in the application of nanotechnology to drug delivery, specifically with the purpose of improving HIV therapy.
In line with our focus this month on all aspects of influenza, we spoke to Ed Schmidt, project manager of the Universal Influenza Vaccines Secured (UNISEC) consortium, about its aim to develop a universal flu vaccine.
Researchers have reported an acceptable safety and immunogenicity profile of an Ebola vaccine in adults and potentially in children in Africa – indicating that the vaccine produces an immune response and is considered safe.
Blood samples from US athletes and staff who travelled to Rio de Janeiro, Brazil, for the 2016 Summer Games were not infected with Zika virus but tested positive for other viral infections, including West Nile Virus, dengue and chikungunya.
In our latest piece, Janet Daly discusses the species jump of influenza A virus from horses to dogs and the insights this gives into the factors involved in interspecies transmission events.
Magnus Evander gives past, present and future perspectives on Inkoo virus – a mosquito-borne virus in northern Europe causing fever and meningoencephalitis.
A new DNA-based Zika vaccine, GLS-5700, has been reported as safe and immunogenic in Phase I trial, according to new research.
Researchers have developed a novel compound, L-HIPPO, which can prevent viral budding in HIV-infected cells. It has been suggested this compound could supplement existing ‘kick and kill’ strategies, allowing complete eradication of HIV in the body.